Dysregulation of CCN3 (NOV) expression in the epidermis of systemic sclerosis patients with pigmentary changes.


Journal

Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927

Informations de publication

Date de publication:
11 2020
Historique:
received: 31 03 2020
revised: 04 06 2020
accepted: 30 06 2020
pubmed: 8 7 2020
medline: 13 8 2021
entrez: 8 7 2020
Statut: ppublish

Résumé

Systemic sclerosis (SSc) is a severe disease whose pathophysiology remains partly unknown, combining autoimmune, vascular, and fibrotic features. Recently, we evidenced a link between vasculopathy and pigmentary changes in SSc. CCN3 (NOV) is a matricellular protein implicated in both angiogenesis and pigmentation regulation, in particular melanocyte adhesion to the basal layer. We decided to study CCN3 expression in SSc epidermis. We show that in SSc patients with pigmentary changes compared to patients with normal pigmentation, CCN3 is specifically downregulated in situ in melanocytes and upregulated in keratinocytes. Moreover, the number of melanocytes is significantly decreased in SSc patients with a disease duration of more than 5 years compared to the other patients. Altogether, our findings could provide new insights on the mechanisms of pigmentary changes in SSc patients, as well as treatment adaptation in a personalized manner.

Identifiants

pubmed: 32633087
doi: 10.1111/pcmr.12912
doi:

Substances chimiques

CCN3 protein, human 0
Nephroblastoma Overexpressed Protein 0

Types de publication

Letter Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

895-898

Informations de copyright

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Pauline Henrot (P)

Inserm, BMGIC, UMR1035, University of Bordeaux, Bordeaux, France.
Department of Rheumatology, National Reference Center for Systemic Autoimmune Rare Diseases, Hopital Pellegrin, place Amélie Raba-Léon, Bordeaux, France.

Catherine Pain (C)

Inserm, BMGIC, UMR1035, University of Bordeaux, Bordeaux, France.

Alain Taïeb (A)

Inserm, BMGIC, UMR1035, University of Bordeaux, Bordeaux, France.
Department of Dermatology and Pediatric Dermatology, National Center for Rare Skin Disorders, Hôpital Saint André, Bordeaux, France.

Marie-Elise Truchetet (ME)

Department of Rheumatology, National Reference Center for Systemic Autoimmune Rare Diseases, Hopital Pellegrin, place Amélie Raba-Léon, Bordeaux, France.
CNRS, Immunoconcept, UMR 5164, University of Bordeaux, Bordeaux, France.

Muriel Cario (M)

Inserm, BMGIC, UMR1035, University of Bordeaux, Bordeaux, France.
Department of Dermatology and Pediatric Dermatology, National Center for Rare Skin Disorders, Hôpital Saint André, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH